Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter.
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) last announced its earnings results on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.06. On average, analysts expect Outlook Therapeutics to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Outlook Therapeutics Price Performance
Shares of NASDAQ:OTLK opened at $1.83 on Wednesday. Outlook Therapeutics has a 12 month low of $0.87 and a 12 month high of $12.85. The stock has a market cap of $58.36 million, a price-to-earnings ratio of -0.20 and a beta of 0.58. The stock’s 50 day moving average price is $1.87 and its 200 day moving average price is $4.81.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on Outlook Therapeutics
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Recommended Stories
- Five stocks we like better than Outlook Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- How to Calculate Stock Profit
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.